|
Patients | Fever at first day of admission | Duration of cough (days) | SpO2 at admission in room air | Chest X-ray | Respiratory care | Antimicrobial therapy | Complications | Length of stay in hospital (days) | Outcome (GOS) |
|
1 | | 8 | 78% | Pneumothorax | O supplementation by Ventimask | Ceftriaxone, Clarithromycin, and Oseltamivir | None | 11 | 5 |
|
2 | | 6 | 78% | Pneumonia | CPAP by Helmet (1 day) + by Ventimask | Ceftriaxone, Oseltamivir | None | 10 | 5 |
|
3 | | 8 | 70% | Interstitial pneumonia, pleural effusion | NIV by full-face mask, EI/MV (2 days ), CPAP by Helmet (4 days) | Ceftriaxone, Clarithromycin, and Oseltamivir | Pneumorrachis | 19 | 5 |
|
4 | | 6 | 81% | Pneumonia | supplementation by Ventimask | Ceftriaxone, Oseltamivir | None | 9 | 5 |
|
5 | | 7 | 82% | Bilateral pulmonary infiltrates | supplementation by Ventimask | Ceftriaxone, Oseltamivir | None | 9 | 5 |
|
6 | | 7 | 50% | Bilateral pulmonary consolidation | EI/MV (11 days), CPAP by Helmet (4 days) | Ceftriaxone, Clarithromycin, and Oseltamivir | None | 27 | 5 |
|
7 | | 6 | 76% | Bilateral pulmonary infiltrates | supplementation by Ventimask | Ceftriaxone, Oseltamivir | Pneumomediastinum | 11 | 5 |
|
8 | | 5 | 82% | Pneumonia | supplementation by Ventimask | Ceftriaxone, Oseltamivir | Pneumopericardium | 18 | 5 |
|
9 | | 9 | 73% | Pneumothorax, bilateral pulmonary consolidation | NIV by full-face mask | Ceftriaxone, Oseltamivir | None | 18 | 5 |
|
10 | | 7 | 90 | Interstitial pneumonia | O2 supplementation | Klaritromicin, Oseltamivir | None | 7 | 5 |
|
11 | | 4 | 92 | Normal | O2 supplementation | Oseltamivir | None | 4 | 5 |
|
12 | | 5 | 94 | Normal | None | Oseltamivir | None | 3 | 5 |
|
13 | | 5 | 95 | Normal | None | Oseltamivir | None | 3 | 5 |
|
14 | | 6 | 91 | Hyperinflated lung | O2 supplementation | Oseltamivir | None | 6 | 5 |
|
15 | | 6 | 93 | Normal | None | Oseltamivir | None | 3 | 5 |
|